{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:56:54Z","timestamp":1793210214147,"version":"4.5.0"},"reference-count":83,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T00:00:00Z","timestamp":1359331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute pulmonary exacerbations (APE) are well\u2010described complications of cystic fibrosis (CF) and are associated with progressive morbidity and mortality. Despite aggressive management with two or more intravenous anti\u2010pseudomonal agents, approximately 25% of exacerbations will result in a loss of lung function. The aim of this review is to provide an overview of the classes of intravenous anti\u2010pseudomonal antibiotics, the findings of anti\u2010pseudomonal antibiotic utilization surveys, the current antibiotic dosing recommendations from the U.S. and Europe, and the pharmacokinetic (PK) and pharmacodynamic (PD) differences between CF and non\u2010CF individuals. Anti\u2010pseudomonal antibiotic classes include beta\u2010lactams, aminoglycosides, fluoroquinolones, and colistimethate sodium. Recent surveys of antibiotic utilization in CF Foundation\u2010accredited care centers have shown that a large number of centers are not following recommended dosing strategies despite published recommendations in the U.S. and Europe. The recommended doses for anti\u2010pseudomonal antibiotics may be higher than FDA\u2010approved doses due to PK and PD differences. As a large portion of CF patients will not regain their lung function following an APE, it seems possible that currently available anti\u2010pseudomonal agents are being used sub\u2010optimally. As new anti\u2010pseudomonal agents are not currently available, we suggest the need to optimize antibiotic dosing and dosing regimens used to treat pulmonary exacerbations in an effort to improve outcomes for CF patients infected with <jats:italic>Pseudomonas aeruginosa<\/jats:italic>. Pediatr Pulmonol. 2013; 48:525\u2013537. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ppul.22757","type":"journal-article","created":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T14:35:41Z","timestamp":1359383741000},"page":"525-537","source":"Crossref","is-referenced-by-count":29,"title":["Optimization of anti\u2010pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary"],"prefix":"10.1002","volume":"48","author":[{"given":"Jeffery T.","family":"Zobell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Dustin","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krow","family":"Ampofo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Stockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.T.","family":"Sherwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Spigarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607183350307"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200304-505SO"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1_suppl.250S"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.4187\/aarc0443"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311003"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043900"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400104"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1421"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.13.1749"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200502-218OC"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-664OC"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22655"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22669"},{"key":"e_1_2_8_16_2","article-title":"Optimization of anti\u2010pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones","author":"Stockmann C","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22664"},{"key":"e_1_2_8_18_2","article-title":"Optimization of anti\u2010pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. aminoglycosides","author":"Young DC","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16d30.x"},{"key":"e_1_2_8_20_2","unstructured":"Trust UCF. Antibiotic treatment for cystic fibrosis in UK Cystic Fibrosis Trust Antibiotic Working Group. 2009."},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21198"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21117"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21374"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1421OC"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0917"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2011.161117"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20985"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21467"},{"key":"e_1_2_8_29_2","first-page":"262","article-title":"National survey of extended\u2010interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations","volume":"16","author":"Prescott WA","year":"2011","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.1.93"},{"key":"e_1_2_8_31_2","first-page":"1219","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Chambers HF","year":"2001"},{"key":"e_1_2_8_32_2","unstructured":"FoundationCF.Microbiology and infectious disease in cystic fibrosis in Cystic Fibrosis Foundation Consensus Conference. 1994."},{"key":"e_1_2_8_33_2","article-title":"Intermittent and extended\u2010infusion Beta\u2010Lactam utilization in cystic fibrosis","author":"Zobell JT","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17906-9"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199701000-00033"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2010.04.003"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00174-09"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1950030212"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01963771"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365549209052615"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2007.07.001"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.4.2336"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.12.1252"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835040-00004"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1950010504"},{"key":"e_1_2_8_46_2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00006454-198712000-00009","article-title":"Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics","volume":"6","author":"Prandota J","year":"1987","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.11"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01647751"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008634911114"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835060-00003"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.1.29"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2006.05.015"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140110-00002"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100051"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100248"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100235"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100215"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki079"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544020-00005"},{"key":"e_1_2_8_60_2","unstructured":"FAO\/WHO\/OIE.2008.Joint FAO\/WHO\/OIE Expert Meeting on Critically Important Antimicrobials. Report of a meeting held in FAO Rome Italy 26\u201330 November 2007.FAO Rome Italy and WHO Geneva Switzerland."},{"key":"e_1_2_8_61_2","unstructured":"Testing E.C.o.A.S. Setting breakpoints for existing antimicrobial agents EUCAST SOP 2.0 2010;http:\/\/www.eucast.org."},{"key":"e_1_2_8_62_2","unstructured":"Testing E.C.o.A.S. Breakpoint tables for interpretation of MICs and zone diameters 2011; EUCAST."},{"key":"e_1_2_8_63_2","unstructured":"Institute C.a.L.S. Performance Standards for Antimicrobial Susceptibility Testing: Twenty\u2010First International Supplement M 100\u2010S21 2011; CLSI: Wayne PA."},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1086\/426189"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.16.1252.30876"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(84)80074-1"},{"key":"e_1_2_8_68_2","unstructured":"Azactam\u00ae Approved Package labeling 2010 Bristol Meyers Squibb."},{"key":"e_1_2_8_69_2","unstructured":"Doribax\u00ae Approved Package labeling 2009 Ortho McNeil Janssen."},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(80)80157-0"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1950040403"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01477-06"},{"key":"e_1_2_8_73_2","unstructured":"Zosyn\u00ae Approved Package labeling 2009 Wyeth."},{"key":"e_1_2_8_74_2","unstructured":"Timentin\u00ae Approved Package labeling 2010 GlaxoSmitKline."},{"key":"e_1_2_8_75_2","unstructured":"Cipro\u00ae Approved Package labeling 2008 Bayer."},{"key":"e_1_2_8_76_2","unstructured":"Colistimethate sodium approved package labeling 2010 X\u2010Gen Pharmaceuticals."},{"key":"e_1_2_8_77_2","unstructured":"Fortaz\u00ae Approved Package labeling. 2010 GlaxoSmithKline."},{"key":"e_1_2_8_78_2","unstructured":"Maxipime\u00ae Approved Package lableling 2009 Bristol Meyers Squibb."},{"key":"e_1_2_8_79_2","unstructured":"Primaxin\u00ae Approved Package labeling 2009 Merck."},{"key":"e_1_2_8_80_2","unstructured":"Merrem\u00ae Approved Package labeling 2009 AstraZeneca."},{"key":"e_1_2_8_81_2","unstructured":"Amikacin sulfate approved package labeling 2007 Bedford Laboratories."},{"key":"e_1_2_8_82_2","unstructured":"Gentamicin sulfate approved package labeling 2007 Braun Medical Inc."},{"key":"e_1_2_8_83_2","unstructured":"Tobramycin sulfate approved package labeling 2008 APP Pharmaceuticals LC."},{"key":"e_1_2_8_84_2","unstructured":"Levaquin\u00ae Approved Package labeling 2011 Ortho\u2010McNeil\u2010Janssen Pharmaceuticals Inc."}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fppul.22757","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.22757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T06:23:47Z","timestamp":1700634227000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.22757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,28]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1002\/ppul.22757"],"URL":"https:\/\/doi.org\/10.1002\/ppul.22757","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,28]]}}}